MCX Hits Record High: SEBI RA Palak Jain Sees 50% Upside In Next Three Months

The analyst forecasts continued bullish momentum, as the stock has broken out above key resistance levels, triggering buying interest.
In this photo illustration, a Multi Commodity Exchange company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)
In this photo illustration, a Multi Commodity Exchange company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)
Profile Image
Preeti Ayyathurai·Stocktwits
Updated Jul 02, 2025 | 8:31 PM GMT-04
Share this article

Shares of commodity exchange player Multi Commodity Exchange of India (MCX) surged 6% on Wednesday to hit a record high. This comes after global brokerage UBS raised its target price to ₹10,000, indicating 21% upside, driven by strong financials and new product launches. 

The regulatory approval for electricity derivatives is expected to unlock fresh hedging tools. MCX reported a 54.2% profit increase in Q4 FY25, beating expectations.

MCX shares have rallied 33% in the last one month. 

SEBI-registered analyst Palak Jain predicts further upside potential, with targets set at ₹11,145.34 to ₹12,829.92 in the next three months. 

She observed that the stock has broken out above key resistance levels, triggering buying interest. Jain pegged support between ₹8,200-₹8,300, with resistance at ₹9,000-₹9,200. 

She concludes that a bullish trend is expected, and investors are advised to monitor the stock closely.

Data on Stocktwits shows that retail sentiment has turned ‘bullish’ on this counter this week.

Screenshot 2025-06-25 142605.png
MCX sentiment and message volume on June 25 as of 2:30 pm IST. | source: Stocktwits

Year-to-date, MCX shares have gained 38%.

Subscribe to The Daily Rip India
All Newsletters
The most relevant Indian markets intel delivered to you everyday.

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Read about our editorial guidelines and ethics policy